drugset
drugset / Trial / NCT06326645

Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome

NCT06326645 ↗

Phase 0 Recruiting 6 enrolled Lindsey Russell, MD Napo Pharmaceuticals, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The objectives of this study are to evaluate the efficacy and safety of crofelemer treatment in adults affected by Short Bowel Syndrome (SBS) with an ileostomy on parenteral support (PS) in reducing output or PS needs. Crofelemer will be provided as a powder three times daily for 12 weeks and a 4 week follow up. .

Timeline

Start
2025-03-03
Primary completion
2026-02-01
Completion
2026-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Crofelemer Small molecule — Oral

Indications

short bowel syndrome